MedTrace Logo

Individual Patient Compassionate Use of Nirogacestat

NCT05041036 · Status: AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2026-05-08

No results posted yet for this study

Summary

This program is being offered on a patient by patient basis and will require company, Institutional Review Board/Independent Ethics Committee, and applicable competent authority approval.

Conditions

  • Desmoid Tumor
  • NOTCH Gene Mutation Positive Tumors

Interventions

DRUG

Nirogacestat (Gamma Secretase Inhibitor)

Patients will receive nirogacestat tablets to be taken orally.

Sponsors & Collaborators

  • SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany

    lead INDUSTRY

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05041036 on ClinicalTrials.gov